LYRAHealthcareNano-Cap

Lyra Therapeutics, Inc. Insider Trading Activity

Every SEC Form 4 insider transaction reported for Lyra Therapeutics, Inc. (LYRA), sourced directly from SEC EDGAR and updated as new filings are accepted.

Last updated:

Quick Answer

Are LYRA insiders buying or selling?

Lyra Therapeutics, Inc. insiders reported 17 open-market buys ($84.7M) and 6 sells ($555.1K) across 23 Form 4 filings — a net buying position of $84.2M.

Source: SEC EDGAR Form 4

Key Statistics (as of Jan 8, 2026)

Total Form 4 filings
23
SEC EDGAR
Insider filers
10
Insider buys (17)
$84.7M
Insider sells (6)
$555.1K

Insider sentiment

Net buying

Net insider flow of $84.2M in net buying.

Recent LYRA insider transactions

DateInsiderRoleTypeSharesPriceValue
Jan 8, 2026Jason CavalierChief Financial OfficerSale769$3.36$2.6K
Jan 8, 2026Maria PalasisPresident & CEOSale1.7K$3.36$5.7K
Nov 13, 2025Joseph Edelman10% OwnerSale45.9K$3.98$182.5K
Nov 10, 2025Joseph Edelman10% OwnerSale70.4K$4.89$344.2K
Jul 15, 2025Maria PalasisPresident & CEOSale1.6K$8.91$13.9K
Jul 15, 2025Jason CavalierChief Financial OfficerSale684$8.91$6.1K
Nov 13, 2023Harlan WaksalExecutive ChairPurchase25.0K$2.96$74.1K
Jun 2, 2023Richard A Damore10% OwnerPurchase1.8M$2.43$4.4M
Jun 2, 2023Edward T AndersonDirector, 10% OwnerPurchase1.8M$2.43$4.4M
Jun 2, 2023Joseph EdelmanDirector, 10% OwnerPurchase3.6M$2.49$9.0M
Jun 13, 2022Ann C MerrifieldDirectorPurchase4.0K$5.05$20.2K
May 17, 2022Ann C MerrifieldDirectorPurchase3.8K$4.83$18.5K
Apr 14, 2022Joseph EdelmanDirector, 10% OwnerPurchase5.9M$4.22$25.0M
Apr 14, 2022Richard A Damore10% OwnerPurchase2.4M$4.22$10.0M
Apr 14, 2022Edward T AndersonDirector, 10% OwnerPurchase2.5M$4.22$10.5M
Apr 13, 2022Harlan WaksalExecutive ChairPurchase237.0K$4.22$1000.0K
Jun 22, 2021Ann C MerrifieldDirectorPurchase3.5K$8.97$31.4K
Dec 17, 2020Nancy Lynn Snyderman MDDirectorPurchase1.0K$9.72$10.0K
May 29, 2020Joseph EdelmanDirector, 10% OwnerPurchase625.0K$16.00$10.0M
May 15, 2020Soleus Private Equity GP I, LLC10% OwnerPurchase138.1K$16.00$2.2M
May 6, 2020NBVM GP, LLC10% OwnerPurchase225.8K$16.00$3.6M
May 6, 2020Edward T AndersonDirector, 10% OwnerPurchase225.8K$16.00$3.6M
May 6, 2020Polaris Venture Management Co. V, L.L.C.10% OwnerPurchase52.8K$16.00$845.2K

Showing the 23 most recent of 23 Form 4 filings for Lyra Therapeutics, Inc..

Most active LYRA insiders

  • Joseph Edelman5 filings
  • Ann C Merrifield3 filings
  • Edward T Anderson3 filings
  • Richard A Damore3 filings
  • Harlan Waksal2 filings

Ask anything about LYRA insider activity

Use Trabud's AI agent to query Lyra Therapeutics, Inc.'s Form 4 history in plain English — "Show me LYRA CEO purchases this year" or compare it against any other ticker.

Open the AI agent

LYRA insider trading FAQ

Are Lyra Therapeutics, Inc. insiders buying or selling?

Across 23 SEC Form 4 filings, Lyra Therapeutics, Inc. (LYRA) insiders reported 17 open-market purchases totaling $84.7M and 6 sales totaling $555.1K. That is a net buying position of $84.2M.

How many insiders trade LYRA stock?

10 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Lyra Therapeutics, Inc.. The most recent filing was accepted on Jan 8, 2026.

Where does Trabud get LYRA insider trading data?

All LYRA insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.

Looking for another company? Browse all tracked companies.

Related Content